| Biomarkers for psychosis | | Posted Tuesday, November 07, 2006 3:04:03 PM by Blog57 Team | | Psychotic symptoms such as hallucinations, delusions, personality changes, and disorganized thinking occur in several psychiatric disorders, including schizophrenia, bipolar disorder, and psychotic depression. Scientists understand little of what goes wrong in a psychotic person's brain, but hope that brain imaging and systematic characterization of genetic activity and protein composition in the brain might help to shed light on mental diseases, eventually leading to better diagnosis, treatment, and possibly even prevention. A new study by Sabine Bahn and colleagues (Cambridge University) published in the international open-access journal PLoS Medicine provides a step in that direction. The researchers compared the protein composition in the cerebrospinal fluid (the clear body fluid that surrounds the brain and the spinal cord) of 79 patients with different psychotic disorders and 90 mentally healthy individuals who served as controls.... | |
| |
| | | Brain's Filing System Uncovered | | Posted Monday, August 28, 2006 3:04:02 AM by Blog57 Team | | Socks in the sock drawer, shirts in the shirt drawer, the time-honored lessons of helping organize one's clothes learned in youth. But what parts of the brain are used to encode such categories as socks, shirts, or any other item, and how does such learning take place? New research from Harvard Medical School (HMS) investigators has identified an area of the brain where such memories are found. .... | |
| |
| | | Pipeline Insight: Schizophrenia | | Posted Thursday, July 27, 2006 12:55:49 AM by Blog57 Team | | The global schizophrenia market will continue to grow until 2010, when revenues will reach $3.8 billion. However, despite the launch of numerous pipeline schizophrenia drugs, the market will begin to decline thereafter owing to the US launch of generic risperidone in 2007, followed by generic versions of olanzapine, quetiapine and ziprasidone from 2011 onwards. Scope Detailed pipeline analysis for key products in development for schizophrenia, plus drug sales forecasts to 2015 Overview of patient potential, segmentation by indication and unmet needs in schizophrenia across the US, EU and Japan Benchmarking of key product and company attractiveness of late-phase pipeline products Detailed clinical trial information and opinions from key thought leaders Highlights By 2015, prospective players can expect to face stiff competition from numerous generic atypical antipsychotics.... | |
| |
| |
|
|
